FABRICO TECHNOLOGY, INC. — Department of Defense SBIR Phase I: The majority of battlefield wounds are attributed to soft tissue injuries. Currently NO tr

Description

The majority of battlefield wounds are attributed to soft tissue injuries. Currently NO treatment is available to regenerate large volumes of muscle. To address this need, Fabrico Technology Inc and the University of Texas at Austin proposes to develop a large volume Electrophoretic Decellularization Chamber (EDC) to produce Electrophoretic Decellularized Bio-Scaffold (EDBS) ExtraCellular Matrix (ECM) for use by 3rd-party scientists and companies to regenerate muscle into a deficit areas of varying volumes. The EDC employs new perfusion organ preservation components. The EDC combines a uniform electrical field potential across the tissue with fluid circulation resulting in efficient and optimized decellularization of xenogeneic muscle tissue of various sizes, shapes and weights. The ECM will transmit physiologically relevant forces to the tendons, provide a degradable collagen-based platform for progenitor cell differentiation to muscle, porosity for vascularization, and versatility to customize delivery of growth factors, cytokines and chemokines to optimize regeneration Upon demonstration of these requirements, Fabrico Technology Inc., will proceed with a Phase II clinical development plan which will include the infusion of the EDBS ECM with human mesenchymal stem cells (HMSC) into a surgically transplanted ECM ion into an animal model to validate the use of this biomaterial for musculoskeletal regeneration/treatment.